spacer
home > > current issue
PUBLICATIONS

   
Text
PDF
   
spacer
News and Press Releases

Tagrisso approved in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

AstraZenecaís Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 L858R mutations as detected by an approved test.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patientís particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement